盐酸硫必利联合维生素B12对60例抽动障碍患儿神经功能及心理的影响

目的探讨盐酸硫必利联合维生素B12对60例抽动障碍患儿神经功能及心理的影响。方法选取于我院接受治疗的60例抽动障碍患儿为研究对象,根据治疗方法分为2组,观察组30例,采用盐酸硫必利+静灵口服液+维生素B12治疗,对照组单纯采用盐酸硫必利治疗,观察并对比2组治疗效果。结果随着时间的推移,2组YGTSS评分的减少率均显著增加,第2周、第4周观察组减少率显著高于对照组,差异有统计学意义(P0.05),第8周、第12周则无明显差异(P0.05);入院时2组SAS评分无显著差异,治疗第2、4、8周时,观察组SAS评分显著低于对照组,差异有统计学意义(P0.05),第12周时,2组SAS评分相比无显著性差异;观察组治疗后CSS、MBI评分均显著高于对照组,差异有统计学意义(P0.05)。结论盐酸硫必利联合维生素B12治疗小儿抽动障碍疗效显著,起效快,能够显著改善患儿的心理状况以及神经功能,提高患儿的日常生活能力。     

可乐定透皮贴剂联合盐酸硫必利治疗儿童抽动障碍的疗效分析

目的比较单独用盐酸硫必利和应用盐酸硫必利联合可乐定透皮贴剂治疗儿童抽动障碍(TD)的疗效。方法选取2015年1月至2016年8月河北省儿童医院神经内科门诊就诊的TD患儿107例,按照就诊顺序将其分为观察组56例和对照组51例。对照组给予盐酸硫必利进行治疗,观察组在对照组的基础上加用可乐定透皮贴剂治疗。在治疗前及治疗后2、4、8w分别采用耶鲁综合抽动严重程度量表(YGTSS)进行疗效的评定和对比,同时观察和记录两组患儿不良反应发生情况。结果与治疗前比较,治疗第2、4、8w观察组YGTSS总分均较治疗前降低,而对照组仅第4、8w较治疗前降低(P<均0.05)。治疗第2、4、8w两组YGTSS总分比较,P<0.05。观察组不良反应发生率为8.92%,对照组为7.87%,P>0.05。两组不良反应发生例数分别为5例和4例。结论盐酸硫必利联合可乐定透皮贴剂治疗TD起效快,疗效好,且不良反应发生率无明显差异。     

血浆同型半胱氨酸与迟发性运动障碍的关系

目的:探讨血浆同型半胱氨酸(Hey)与迟发性运动障碍(TD)的关系.方法:对33例伴TD的精神分裂症患者(TD组)与33例不伴,TD的精神分裂症患者(非TD组)进行血浆Hey与血清维生素B12、叶酸水平检测.结果:TD组血浆Hey水平显著高于非TD组,而血清叶酸水平显著低于非TD组.两组血浆Hey水平均与血清维生素B1...     

硫必利对抽动症患儿的效果以及患者家属抑郁、焦虑的变化

目的观察硫必利对小儿抽动症(TS)的临床效果以及患儿家属抑郁、焦虑情绪的相应变化。方法选择2019年3月~2021年3月接诊的106例TS患儿,随机分为:观察组(纳入53例,行硫必利治疗)、对照组(纳入53例,行氟哌啶醇治疗),评价两组患儿耶鲁抽动症整体严重度量表(YGTSS)、家属抑郁及焦虑评分、药物副反应量表(TESS)、临床有效率。结果(1)组间治疗前、治疗10周时的YGTSS评分均无明显差异,P>0.05;(2)治疗前,组间家属抑郁及焦虑评分无明显差异,P>0.05;治疗10周后,观察组家属抑郁及焦虑评分较低,P<0.05;(3)观察组TESS评分治疗2周(0.41±0.11)分、4周(0.68±0.19)分、6周(1.11±0.15)分、8周(1.58±0.32)分、10周(1.86±0.34)分均低于对照组(0.68±0.13)分、(1.03±0.37)分、(1.58±0.22)分、(1.95±0.41)分、(2.36±0.33)分,P<0.05;(4)组间临床有效率无明显差异,P>0.05。结论对TS患儿采用硫必利、氟哌啶醇治疗,二者疗效相当,不过前者不良反应少,能够减轻家属抑郁、焦虑情绪。     

硫必利与利培酮治疗老年痴呆精神行为症状的疗效对比

目的探讨硫必利与利培酮治疗老年痴呆精神行为症状的疗效。方法选择108例老年痴呆患者,随机分为对照组与观察组各54例,对照组给予利培酮100mg/d,观察组给予硫必利2.0mg/d,治疗周期2个月。观察2组治疗前后PANSS评分;对比2组有效率,观察治疗过程中不良反应(嗜睡、头痛、体质量下降、锥体外系反应、易怒、失眠)发生情况。结果2组治疗前PANSS评分比较差异无统计学意义(P0.05),2组治疗7d、15d、30d、60d后PANSS评分比较差异均有统计学意义(P0.05);对照组有效率74.1%,观察组为88.9%,观察组有效率明显高于对照组(P0.05);对照组治疗过程中不良反应发生率25.9%,观察组为9.3%,2组比较差异有统计学意义(P0.05)。结论硫必利、利培酮均对老年痴呆有一定的治疗作用,硫必利更能够改善老年痴呆患者的临床症状,提高有效率,减少不良反应的发生。     

硫必利与纳洛酮治疗酒精所致精神障碍的对照研究

目的 探讨硫必利对酒精所致精神障碍的临床疗效。方法 将符合入组标准的60例患者随机分为两组，分别静滴硫必利和纳洛酮治疗4周，用阳性症状、阴性症状量表（PANSS）和副反应量表（TESS）评定临床疗效和不良反应。结果 硫必利组治疗有效率为93．3％，纳洛酮组有效率为96．7％，两组无显著性差异。结论 硫必利对酒精所致精神障碍的疗效肯定，且不良反应少。     

氨磺必利与喹硫平治疗首发精神分裂症的对照研究

目的探讨氨磺必利治疗首发精神分裂症的疗效及安全性。方法将60例符合国际疾病分类第10版（ICD-10）精神分裂症诊断标准的患者随机分为氨磺必利组与喹硫平组,于治疗前及治疗2、4、6周末进行阳性与阴性症状量表（PANSS）评定,并观察不良反应。结果氨磺必利组与喹硫平组比较,有效率差异无统计学意义（P〉0.05）,两组不良反应均较少。结论氨磺必利治疗精神分裂症安全有效。     

氨磺必利与奎硫平治疗酒精所致精神障碍的临床观察

<正>本研究观察氨磺必利及喹硫平治疗酒精所致精神障碍的疗效和安全性。1对象和方法为2011年1~12月我院门诊及住院的男性酒精所致精神障碍患者67例,均符合CCMD-3诊断标准,阳性与阴性症状量表(PANSS)评分≥60分;排除严重器质性和躯体疾病。随机分为两组,氨磺必利组:33例,年龄(39.2±8.6)岁,饮酒(11.1±7.7)年,病程(5.9±2.9)个月。奎硫平组:34例,年龄(38.1±9.9)岁,饮酒(10.9±8.6)年,病程(6.1±3.1)个月。两组间以上各指标具有可比性。入组前3周均未抗精神病药物治疗;患者及其监护人对本研究知情同意。     

氨磺必利与喹硫平治疗以阴性症状为主的精神分裂症对照观察

目的比较小剂量氨磺必利与喹硫平对以阴性症状为主的精神分裂症的疗效和安全性。方法采用数字随机法将112例以阴性症状为主的精神分裂症患者分为两组各50例,分别给予氨磺必利与喹硫平治疗,疗程8周,采用阳性与阴性症状量表(PANSS)、阴性症状评定量表(SANS)评定疗效,以副反应量表(TESS)评定不良反应。结果治疗8周氨磺必利组显效率为55.40%,两组PANSS阳性症状、阴性症状评分差异有统计学意义(P<0.01);两组SANS各因子分及总分差异有统计学意义(P<0.01)。结论小剂量氨磺必利对以阴性症状为主的精神分裂症有较好的疗效和安全性。     

穴位注射联合神经生长因子治疗特发性面神经麻痹临床观察

目的探讨特发性面神经麻痹采用穴位注射联合鼠神经生长因子治疗的临床效果。方法选取黄冈市中心医院2015-01—2016-10收治的特发性面神经麻痹患者60例,根据治疗方案的不同分为2组,其中30例实施维生素B1、B12、氢溴酸加兰他敏混合穴位注射治疗为对照组,30例实施维生素B1、B12、氢溴酸加兰他敏混合穴位注射联合鼠神经生长因子肌内注射治疗为观察组;观察2组用药前后面部神经功能评分和临床疗效。结果 2组治疗前面神经功能评分比较差异无统计学意义(P0.05),治疗后,面神经功能评分均有所升高,观察组评分显著高于对照组,观察组治疗各时间点总有效率(63.3%、80.0%及93.3%)显著高于对照组(46.7%、66.7%及76.7%),差异有统计学意义(P0.05)。结论穴位注射联合鼠神经生长因子治疗特发性面部神经麻痹,有效的改善了患者的面部神经功能障碍,效果显著。     

Satisfaction with quality of life varies with temperament types of patients with schizophrenia

We sought to explore the relationships of three temperament factors with domain-specific subjective quality of life (QOL) of patients with schizophrenia. Ninety patients with schizophrenia were evaluated using the Quality of Life Enjoyment and Life Satisfaction Questionnaire, the Tridimensional Personality Questionnaire, the Positive and Negative Syndromes Scale, the Distress Scale for Adverse Symptoms, the Insight and Treatment Attitudes Questionnaire, the Insight Self-Report Scale, and standardized questionnaires for self-reported emotional distress and stress process-related variables. Predictors of domain-specific QOL were identified using multiple regression techniques. Temperament factors explain 6% to 16% of variability in QOL domain scores among patients with schizophrenia after controlling for the remaining variables (emotional distress, social support, self-esteem, avoidance coping, age, side effects, and depression). We found that higher levels of novelty seeking are associated with better general QOL, physical health, and more positive subjective feelings, whereas higher levels of reward dependence are related to better satisfaction from social relationships. Higher levels of harm avoidance are associated with poorer satisfaction with general activities, and medication. Thus, temperament factors, as assessed by the Tridimensional Personality Questionnaire, substantially influence satisfaction with life quality in schizophrenia. Novelty seeking, reward dependence, and harm avoidance are associated with different domains of QOL.     

Compliance with health regimens of adolescents with epilepsy

The purpose of this paper was to describe the compliance of adolescents with epilepsy and some factors connected to it. Altogether 300 individuals with epilepsy aged 13-17 years were randomly selected from the Finnish Social Insurance Institution's register. Every fifth person on the list was included in the sample. Seventy-seven per cent (n= 232) of the selected adolescents with epilepsy returned a questionnaire sent to them relating to compliance. The data were analysed using the SPSS software. Twenty-two per cent of the adolescents with epilepsy felt that they complied fully with their suggested health regimens, while 44% placed themselves in the category of "satisfactory compliance", and the remaining 34% reported poor compliance. Compliance with their recommended life-style was poorest, while the highest degree of compliance was recorded for medication. Background variables, such as the duration of the disease, exercise, smoking, alcohol-intake and the number of seizures, were statistically significantly related to compliance (P< 0.001). Good motivation, a strong sense of normality, experience of results, subjective outcome, energy and will-power, support from parents, physicians and nurses, and a positive attitude towards to the disease and its treatment, no threat to social and emotional well-being and no fears of complications and no fear of seizures explained good compliance (P< 0.001).     

Treatment of patients with tardive dystonia with olanzapine

Tardive dystonia represents a complication of long-term use of neuroleptics and its treatment is often unsatisfactory. Atypical neuroleptics appear to improve tardive dystonia, and cases of tardive dystonia successfully managed with clozapine have been reported. The aim of this open-label video-blinded study was to evaluate the antidystonic efficacy of olanzapine, a new atypical neuroleptic with a low risk of agranulocytosis, in a group of four patients (one man and three women) with tardive cervical dystonia. They developed severe dystonia after several years of neuroleptic treatment. Extensive laboratory evaluations, as well as neurophysiologic and neuroradiologic investigations, were negative. Olanzapine was started at a dose of 5 mg/d and increased up to 7.5 mg/d. All patients were evaluated at baseline and after 2, 4, 8, and 12 weeks of treatment, using the Toronto Western Spasmodic Torticollis Rating Scale, and videotaped. At the end of the trial, the videotapes were reviewed and scored by a blind observer. A self-rating visual analog scale completed the disability evaluation.A moderate to marked improvement in dystonia was observed in all patients, and significant differences were observed in Toronto Western Spasmodic Torticollis Rating Scale scores and videotape ratings after 8 and 12 weeks of treatment compared with the basal values (p < 0.05). The average percentage of improvement in Toronto Western Spasmodic Torticollis Rating Scale score and visual analog scale was 26.4% and 42.6%, respectively. No serious side effects were reported at the maximum dosage reached (7.5 mg/d). This study warrants a larger controlled study to conclusively demonstrate the efficacy of olanzapine in tardive dystonia.     

Factors associated with stigmatization of persons with mental illness

Stigmatization of individuals with mental illnesses is widespread and serves as a major barrier to treatment. In a survey of 116 undergraduates, the authors examined the impact of diagnosis, attitudes about treatment, and psychiatric terminology on stigma associated with mental illness. Stigmatization of schizophrenia was significantly higher than stigmatization of depression. More positive attitudes toward treatment were associated with significantly less stigma. However, psychiatric terminology had no impact on attitudes toward mental illness. Significantly less stigmatization of mental illness was found among females than among males. Reducing the stigmatization of mental illness continues to be an important goal for mental health professionals.